


PHARMACEUTICAL 2023



Akebia Therapeutics Inc. Rank 316 of 446





PHARMACEUTICAL 2023

Akebia

Akebia Therapeutics Inc. Rank 316 of 446

The relative strengths and weaknesses of Akebia Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Akebia Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Akebia Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 102% points.

The company's Economic Capital Ratio, given in the ranking table, is -22%, being 65% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	184,949
Cost of Goods Sold	84,796
Intangible Assets	55,053
Liabilities, Current	124,756
Liabilities, Non-Current	118,496
Other Assets	106,614
Other Compr. Net Income	0
Other Expenses	19,108
Other Liabilities	99,236
Other Net Income	-13,447
Other Revenues	292,602
Property and Equipment	5,214
Research and Development	129,114
Selling, General and Administrative Expense	138,699

Output Variable	Value in 1000 USD
Assets	351,830
Liabilities	342,488
Expenses	371,717
Revenues	292,602
Stockholders Equity	9,342
Net Income	-92,562
Comprehensive Net Income	-92,562
Economic Capital Ratio	-22%

